Artwork

Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Treatment of Complicated Staphylococcus aureus Bacteremia

11:35
 
Share
 

Manage episode 500027600 series 96523
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.Related Content:

  continue reading

443 episodes

Artwork
iconShare
 
Manage episode 500027600 series 96523
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.Related Content:

  continue reading

443 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play